Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 11/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8862880 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TDP1CTBP2CA2SMN1; SMN2 | |
| SCHEMBL11328029 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TDP1CA2SMN1; SMN2MMP1 | |
| SCHEMBL11328030 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TDP1CA2SMN1; SMN2MMP1 | |
| SCHEMBL10976692 | 0.76 | CA1 (0.44) | CTBP2 | |
| SCHEMBL10976708 | 0.76 | CA1 (0.44) | CTBP2 | |
| SCHEMBL11417638 | 0.75 | ALDH1A1 (0.37) | ALDH1A1TDP1CTBP2CA2SMN1; SMN2 | |
| SCHEMBL11417640 | 0.75 | ALDH1A1 (0.37) | ALDH1A1TDP1CTBP2CA2SMN1; SMN2 | |
| SCHEMBL25119763 | 0.75 | ALDH1A1 (0.37) | ALDH1A1TDP1CTBP2CA2MMP1 | |
| SCHEMBL30216812 | 0.75 | ALDH1A1 (0.37) | ALDH1A1TDP1CTBP2CA2MMP1 | |
| Malonic Acid SCHEMBL9026618 | 0.74 | LDHA (0.35) | ALDH1A1TDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113286795-B | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4155301-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-5607934-A | PREVENTING AND TREATING DISEASES CAUSED BY SUPEROXIDE RADICALS, NEPHRITIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0411150-B1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMA CO LTD (JP) | 1996-11-27 | — | — | EP | disclosed |
| CN-1112364-A | Piperazine derivatives and salts thereof | OTSUKA PHARMA CO LTD (JP) | 1995-11-22 | — | — | CN | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0659182-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
| WO-1995002593-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-26 | — | — | WO | disclosed |
| CN-1024797-C | Indole derivatives | OTSUKA CHEMICAL CO LTD (JP) | 1994-06-01 | — | — | CN | disclosed |
| US-5238938-A | Nephrosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| CN-1049155-A | INDOLE DERIVATIVES | OTSUKA CHEMICAL CO LTD (JP) | 1991-02-13 | — | — | CN | disclosed |
| EP-0411150-A1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | PRMT5, PRMT3, PRMT1 | ALDH1A1 3595/4885TDP1 1652/4885CTBP2 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.